CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1413-1419

  Kim, Young Yim ^a,b   Park, Chul Kee ^a,b   Kim, Seung Ki ^a,b   Phi, Ji Hoon ^a,b   Kim, Jin Hyun ^c   Kim, Chae Yong ^a,d   Wang, Kyu Chang ^a,b   Cho, Byung Kyu ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

Belotecan; Camptothecin analogue; CKD 602; Malignant glioma; Topoisomerase 1 inhibitor

Indexed keywords

BELOTECAN; 7 (2 (N ISOPROPYLAMINO)ETHYL)CAMPTOTHECIN; 7-(2-(N-ISOPROPYLAMINO)ETHYL)CAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; BRAIN TUMOR; CELL CYCLE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GLIOBLASTOMA; PATHOLOGY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CAMPTOTHECIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; INHIBITORY CONCENTRATION 50; TIME FACTORS;

EID: 67649997027     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000369     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent M J, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Gomez-Manzano C, Alonso MM, Alfred Yung WK, et al: Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12: 556-562, 2006.
3. D'Arpa P, Beardmore C and Lui F: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50: 6919-6924, 1990.
4. Friedman HS, Keir ST and Houghton PJ: The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 97: 2359-2362, 2003.
5. Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T and Nagao S: Quantitative analysis of DNA-topoisomerae-I activity in human and rat glioma: characterization and mechanism of resistance to anti-topoisomerase chemical, camptothecin-11. J Surg Oncol 53: 97-103, 1993.
6. Thompson J, George EO, Poquette CA, et al: Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. Clin Cancer Res 5: 3617-3631, 1999.
7. Bissery MC, Vrignaud P, Lavalle F and Chabot GG: Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7: 437-460, 1996.
8. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J Am Chem Soc 88: 3888-3890, 1966.
9. Gottlieb JA, Guarino AM, Call JB Oliverio VT and Block JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium. Cancer Chemother Rep 54: 461-467, 1970.
10. Muggia FM, Creven PJ, Hansen HH, Cohen MH and Selawry OS: Phase I clinical trial of weekly and daily treatment with camptothecin. Cancer Chemother Rep 56: 515-521, 1972.
11. Moertel CG, Schutt AJ, Reitmeier RJ and Hahn RG: Phase II study of camptothecin in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95-101, 1972.
12. Kolimannsberger C, Mross K, Jakob A, Kanz L and Bokemeyer C: Topotecan - a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56: 1-12, 1999.
13. Mathijssen RH, Loos WJ, Verweij J and Sparreboom A: Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2: 103-123, 2002.
14. Josson E, Dhar S, Josson B, Nygren P, Graf W and Larsson, R: Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines. Eur J Cancer 36: 2120-2217, 2000.
15. Reardon DA, Quinn JA, Rich JN, et al: Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neurooncology 6: 134-144, 2004.
16. Klaute G, Schütze M, Bombor I, Benecke R, Piek J and Fietkau R: Concurrent chemoradiotherapy and adjuvant chemotherapy with Topotecan for patients with glioblastoma multiforme. J Neurooncol 77: 199-205, 2006.
17. Raymond E, Fabbro M, Boige V, et al: Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol 14: 603-614, 2003.
18. Michielin O, Udry E, Périard D, Matzinger O, Lobrinus JA and Stupp R: Irinotecan-induced interstitial pneumonia. Lancet Oncol 5: 322-324, 2004.
19. Lee JH, Lee JM, Kim JK, et al: Antitumor activity of 7-[2-(Nisopropylamino) ethyl]-(20S)-camptothecin, CKD-602 as a potent DNA topoisomerase I inhibitor. Arch Pharm Res 21: 581-590, 1998.
20. Lee JH, Lee JM, Lim KH, Kim JK, Ahn SK, Bang YJ and Hong CI: Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann NY Acad Sci 922: 324-325, 2000.
21. Kim EJ, Lee RK, Suh JE, Han SS and Kim JK: Safety pharmacology of CKD-602, a novel anticancer agent. Arzneimittel Forschung 53: 272-279, 2003.
22. Jew SS, Kim HJ, Kim MG, Rho EY, Park HG, Kim JK, Han HJ and Lee H: Synthesis and antitumor activity of 7-substituted camptothecin analogues. Bioorg Med Chem Lett 6: 845-848, 1996.
23. Lee JH, Sohn YS, Lee JM, Kim JK, Ahn SK, Jew SS, Park JG, and Hong CI: Antitumor activity of CKD602, a novel camptothecin derivative. Proc Am Assoc Cancer Res 39: 303, 1998.
24. Fassberg J and Stella VJ: A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81: 676-684, 1992.
25. ARF, PTEN tumor suppressor gene in human glioma cell lines. Brain Path 9: 469-479, 1999.
26. Jung JY, Song SH, Kim TY, Park JH, Jong HS, Im SA, Kim TY, Bang YJ and Kim NK: The synergism between belotecan and cisplatin in Gastric Cancer. Cancer Res Treat 38: 159-167, 2006.
27. HK Kim, YJ Bang, DS Hoe, SG Shin and NK Kim: Phase I trial of CKD-602, a novel camptothecin derivative, in patients with advanced solid tumor. Proc Am Soc Clin Oncol 21 (abstr 393), 2002.
28. Song Y, Seo SS, Bang YJ, Kang SB, Nam JH, Ryu SY, Lee KH, Park SY, Hong CI and Lee HP: Phase II evaluation of CKD-602, a comptothecin analog administered on a 5-day schedule in patients with recurrent or refractory ovarian cancer. Proc Am Soc Clin Oncol 22 (abstr 1877), 2003.
29. Vredenburgh JJ, Desjardins A, Herndon JE, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 15: 1253-1259, 2007.
30. Feun LG, Marini A, Landy H, Markoe A, Heros D, Robles C, Herrera C and Savaraj N: Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. J Neurooncol 82: 177-181, 2007.
31. Wang Y, Zhu S, Cloughesy TF, Liau LM and Mischel PS: p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene 23: 1283-1290, 2004.
32. O'Connor PM, Jackman J, Bae I, et al: Characterization of p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.
33. Djuzenova CS, Güttler T, Berger S, Katzer A and Flentje M: Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment. Cancer Biol Ther 7: 364-373, 2008.
34. Morandi E, Severini C, Quercioli D, et al: Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines. Mol Cancer 7: 66, 2008.
35. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett GH: Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39: 417-423, 1997.
36. Janss AJ, Levow C, Bernhard EJ, Muschel RJ, McKenna WG, Sutton L and Phillips PC: Caffeine and staurosporine enhance the cytotoxicity of cisplatin camptothecin in human brain tumor cell lines. Exp Cell Res 243: 2-38, 1998.